❌

Normal view

Received — 8 April 2026 ⏭

MuDD: A Multimodal Deception Detection Dataset and GSR-Guided Progressive Distillation for Non-Contact Deception Detection

✇cs.AI, q-bio.NC updates on arXiv.org
By: Peiyuan Jiang · Yao Liu · Yanglei Gan · Jiaye Yang · Lu Liu · Daibing Yao · Qiao Liu
7 April 2026 at 12:00
arXiv:2603.26064v2 Announce Type: replace-cross Abstract: Non-contact automatic deception detection remains challenging because visual and auditory deception cues often lack stable cross-subject patterns. In contrast, galvanic skin response (GSR) provides more reliable physiological cues and has been widely used in contact-based deception detection. In this work, we leverage stable deception-related knowledge in GSR to guide representation learning in non-contact modalities through cross-modal knowledge distillation. A key obstacle, however, is the lack of a suitable dataset for this setting. To address this, we introduce MuDD, a large-scale Multimodal Deception Detection dataset containing recordings from 130 participants over 690 minutes. In addition to video, audio, and GSR, MuDD also provides Photoplethysmography, heart rate, and personality traits, supporting broader scientific studies of deception. Based on this dataset, we propose GSR-guided Progressive Distillation (GPD), a cross-modal distillation framework for mitigating the negative transfer caused by the large modality mismatch between GSR and non-contact signals. The core innovation of GPD is the integration of progressive feature-level and digit-level distillation with dynamic routing, which allows the model to adaptively determine how teacher knowledge should be transferred during training, leading to more stable cross-modal knowledge transfer. Extensive experiments and visualizations show that GPD outperforms existing methods and achieves state-of-the-art performance on both deception detection and concealed-digit identification.
Received — 2 April 2026 ⏭

Points-to-3D: Structure-Aware 3D Generation with Point Cloud Priors

✇cs.AI, q-bio.NC updates on arXiv.org
By: Jiatong Xia · Zicheng Duan · Anton van den Hengel · Lingqiao Liu
1 April 2026 at 12:00
arXiv:2603.18782v3 Announce Type: replace-cross Abstract: Recent progress in 3D generation has been driven largely by models conditioned on images or text, while readily available 3D priors are still underused. In many real-world scenarios, the visible-region point cloud are easy to obtain from active sensors such as LiDAR or from feed-forward predictors like VGGT, offering explicit geometric constraints that current methods fail to exploit. In this work, we introduce Points-to-3D, a diffusion-based framework that leverages point cloud priors for geometry-controllable 3D asset and scene generation. Built on a latent 3D diffusion model TRELLIS, Points-to-3D first replaces pure-noise sparse structure latent initialization with a point cloud priors tailored input formulation.A structure inpainting network, trained within the TRELLIS framework on task-specific data designed to learn global structural inpainting, is then used for inference with a staged sampling strategy (structural inpainting followed by boundary refinement), completing the global geometry while preserving the visible regions of the input priors. In practice, Points-to-3D can take either accurate point-cloud priors or VGGT-estimated point clouds from single images as input. Experiments on both objects and scene scenarios consistently demonstrate superior performance over state-of-the-art baselines in terms of rendering quality and geometric fidelity, highlighting the effectiveness of explicitly embedding point-cloud priors for achieving more accurate and structurally controllable 3D generation. Project page: https://jiatongxia.github.io/points2-3D/
Received — 14 March 2026 ⏭

NFATC2::NUTM2 Fusion Defines a Novel Primary Pulmonary Epithelial Tumor With a Distinctive Immunophenotype

✇Pulmonary nodule
By: Lanlan Feng · Qiao Liu · Xiaoyan Liu · Shumei Wang · Junting Li · Yu Han · Xiaorong Mu · Yuanyuan Wang · Junfeng Jiang · Chun Wu · Xiujuan Han · Shaojun Zhu · Fuqin Zhang · Jing Tian · Zhuo Wang · Wei Zhang · Li Gong
13 March 2026 at 18:00

Am J Surg Pathol. 2026 Jun 1;50(6):695-704. doi: 10.1097/PAS.0000000000002533. Epub 2026 Mar 13.

ABSTRACT

With the application of molecular techniques in pathologic diagnosis, several novel primary pulmonary epithelial tumors have been continuously discovered and classified under the WHO classification of thoracic tumors. Recently, a pulmonary tumor with NFATC2 :: NUTM2B fusion was first documented, but the spectrum of NFATC2::NUTM2 fusion variants and their associated pathologic features remains incompletely characterized. Coincidentally, we also found and described 6 primary pulmonary tumors harboring recurrent NFATC2::NUTM2A/E fusions through integrated genomic analysis. These patients, including 4 females and 2 males, with a median age of 53 years, presented with incidentally detected peripheral lung nodules composed of monotonous epithelioid cells arranged in cords, nests, and trabeculae within a prominent desmoplastic stroma. All tumors exhibited a consistent immunophenotype: CK5/6+/GATA3+/calponin+/EMA+/DOG1 (perinuclear dot-like staining)/p63-. High-throughput chromosome conformation capture (Hi-C) analysis showed the structural variation of NFATC2::NUTM2E in all 6 cases, whereas RNA sequencing detected the fusion transcripts in 5 cases ( NFATC2::NUTM2A , n=2; NFATC2::NUTM2E , n=3). Ultrastructural examination of 1 case suggested epithelial differentiation. All patients remained disease-free after complete resection (median follow-up: 24 mo; range: 9 to 41 mo). These findings define a novel primary pulmonary tumor entity driven by NFATC2::NUTM2 fusions, and characterized by a distinctive immunophenotype, expanding the spectrum of NUTM2 -associated neoplasms. Our study underscores the utility of multiomics approaches for characterizing rare neoplasms and provides a diagnostic framework for this entity.

PMID:41821426 | DOI:10.1097/PAS.0000000000002533

NFATC2::NUTM2 Fusion Defines a Novel Primary Pulmonary Epithelial Tumor With a Distinctive Immunophenotype

✇Omics In Lung
By: Lanlan Feng · Qiao Liu · Xiaoyan Liu · Shumei Wang · Junting Li · Yu Han · Xiaorong Mu · Yuanyuan Wang · Junfeng Jiang · Chun Wu · Xiujuan Han · Shaojun Zhu · Fuqin Zhang · Jing Tian · Zhuo Wang · Wei Zhang · Li Gong
13 March 2026 at 18:00

Am J Surg Pathol. 2026 Mar 13. doi: 10.1097/PAS.0000000000002533. Online ahead of print.

ABSTRACT

With the application of molecular techniques in pathologic diagnosis, several novel primary pulmonary epithelial tumors have been continuously discovered and classified under the WHO classification of thoracic tumors. Recently, a pulmonary tumor with NFATC2::NUTM2B fusion was first documented, but the spectrum of NFATC2::NUTM2 fusion variants and their associated pathologic features remains incompletely characterized. Coincidentally, we also found and described 6 primary pulmonary tumors harboring recurrent NFATC2::NUTM2A/E fusions through integrated genomic analysis. These patients, including 4 females and 2 males, with a median age of 53 years, presented with incidentally detected peripheral lung nodules composed of monotonous epithelioid cells arranged in cords, nests, and trabeculae within a prominent desmoplastic stroma. All tumors exhibited a consistent immunophenotype: CK5/6+/GATA3+/calponin+/EMA+/DOG1 (perinuclear dot-like staining)/p63-. High-throughput chromosome conformation capture (Hi-C) analysis showed the structural variation of NFATC2::NUTM2E in all 6 cases, whereas RNA sequencing detected the fusion transcripts in 5 cases (NFATC2::NUTM2A, n=2; NFATC2::NUTM2E, n=3). Ultrastructural examination of 1 case suggested epithelial differentiation. All patients remained disease-free after complete resection (median follow-up: 24 mo; range: 9 to 41 mo). These findings define a novel primary pulmonary tumor entity driven by NFATC2::NUTM2 fusions, and characterized by a distinctive immunophenotype, expanding the spectrum of NUTM2-associated neoplasms. Our study underscores the utility of multiomics approaches for characterizing rare neoplasms and provides a diagnostic framework for this entity.

PMID:41821426 | DOI:10.1097/PAS.0000000000002533

There are no more articles
❌